Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term atogepant safety study for migraine prevention
NL-OMON59877Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atogepant in migraine, migraine with aura, migraine without aura and 2 more, sponsored by AbbVie Inc. Primary endpoint: Percentage of participants with at least 1 treatment-emergent adverse event. Started Jan 2022; status: completed.
02
Drugs
atogepant
03
Conditions
migrainemigraine with auramigraine without aurachronic migraineepisodic migraine
Beyond the preview
Go deeper on NL-OMON59877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59877.